scholarly journals The Weight of HLA-DPA1 rs3077 Single Nucleotide Polymorphism in Prostate Cancer, a Multicenter Study

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Mohammed Jayed Alenzi ◽  
Amany A. Ghazy ◽  
Diaa-Eldin Taha
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Serum Levels ◽  
Arab Countries ◽  
Control Group ◽  
Single Nucleotide ◽  
Genetic Transmission ◽  
Free Psa ◽  
Protective Allele ◽  
Total Prostate Specific Antigen

Prostate cancer (PCa) has almost the highest genetic transmission that mimics an autosomal dominance hereditary pattern of cancers in some families. Its incidence in Arab countries was reported to be steadily increasing. Aim. To determine the relevance of HLA-DPA1 rs3077 (A/G) SNP with prostate cancer’s risk and/or severity. Subjects and Methods. Forty PCa patients and forty age matched patients with benign prostatic hyperplasia (BPH), as a control group, were enrolled in the study. Serum levels of urea, creatinine, total prostate-specific antigen (PSA), and free PSA were measured. PSA ratio was determined as well. Genotyping of HLA-DPA1 rs3077 (A/G) SNP was done using real-time PCR. Results. The measured lab parameters, except free PSA, were significantly higher among PCa patients in comparison to controls ( P < 0.001 ∗ ). Moreover, PSA ratio was significantly high among PCa patients ( P < 0.001 ∗ ). HLA-DPA1 rs3077 GG genotype was more frequent in PCa patients and the associated OR was 2.546 ( P = 0.059 ), while AA genotype was more frequent in the control group and the associated OR was 0.145 ( P = 0.081 ). Frequency of G allele was higher among PCa patients than the control group while A allele frequency was significantly decreased ( P = 0.034 ∗ ) (protective allele). On multivariate analysis, there is no significant correlation found between HLA-DPA1 rs3077 SNP and PSA ratio (OR = 4.5, 95% CI = 1.2–17.4, P = 0.856 ). Conclusion. HLA-DPA1 rs3077 G allele could be a risk factor for prostate cancer. However, HLA-DPA1 rs3077 SNP has no relation to PCa severity.

Clinically insignificant improvement of prostate cancer prediction by addition of sex steroid hormones and SHBG serum levels to serum PSA, fPSA%, and age in a screening setting

2012 ◽  
Vol 11 (2) ◽  
Author(s):  
Isabel Heidegger ◽  
Marina Popovscaia ◽  
Reinhold Ramoner ◽  
Georg Schäfer ◽  
Birgit Stenzel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Steroid Hormones ◽  
Specific Antigen ◽  
Free Testosterone ◽  
Serum Levels ◽  
Sex Hormone Binding Globulin ◽  
Sex Steroid ◽  
Sex Steroid Hormone ◽  
Cancer Prediction ◽  
Free Psa

AbstractVarious findings implicate sex hormones in prostate growth and development and also in prostate carcinogenesis. We investigated if addition of sex steroid hormone and sex hormone binding globulin (SHBG) serum levels to standard risk assessment parameters [prostate-specific antigen (PSA), free PSA percentage (fPSA%), and age] improves prostate cancer prediction in a PSA screening setting. Steroid hormones testosterone (T), free testosterone (fT), and estradiol (E2), and binding protein SHBG levels were measured in 762 men undergoing prostate biopsy due to suspect PSA serum levels. Prostate cancer was diagnosed in 286 (37.5%) of these men. Our data confirmed that PSA (mean BE=5.09; mean CA=6.05; p=1.24×10

20–25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials – Analysis of 1098 Patients in Four Centers

2009 ◽  
Vol 24 (2) ◽  
pp. 65-69 ◽  
Author(s):  
Carsten Stephan ◽  
Chris Bangma ◽  
Giulio Vignati ◽  
Georg Bartsch ◽  
Michael Lein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
World Health ◽  
Test Results ◽  
Misleading Information ◽  
Free Psa ◽  
Total Prostate Specific Antigen ◽  
Health Organization ◽  
Independent Cohort

Aim To examine the potential clinical implications of the recalibration of total prostate-specific antigen (PSA) and free PSA (fPSA) assays to the World Health Organization (WHO) standard materials. Material and methods Data from 1098 patients with or without clinically detected prostate cancer (PCa) from four independent cohort studies were compared using commercial assays calibrated to the traditional Hybritech® PSA (PSA-Hyb) and fPSA (fPSA-Hyb) standards and to the WHO 96/670 (PSA-WHO) and 96/668 (fPSA-WHO) standards. The Access® Immunoassay System (Beckman Coulter, Inc.) was used in all studies. Results All studies showed 20% to 25% lower PSA and fPSA test results with the WHO-standardized assays. No significant change in %fPSA (fPSA/PSA × 100) was observed. Continuing to use the traditional clinical PSA cutoffs obtained with the Hybritech standard after changing to the PSA-WHO standard could result in up to one-third of prostate cancer cases being missed. Conclusions: Manufacturers should fully inform laboratories about a calibration change and its clinical impact. Laboratory reports for PSA measurements should indicate the assay's manufacturer and which calibration standard was used to avoid misleading information concerning PCa risk

scholarly journals Performance of free prostate-specific antigen ratio in differentiating between prostatic cancer and benign prostatic lesions at a referral hospital in South Africa

2018 ◽  
Vol 60 (4) ◽  
pp. 54
Author(s):  
Boitumelo Phiri-Ramongane ◽  
Ayeaye Khine
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Total Population ◽  
Specific Antigen ◽  
Male Population ◽  
Free Psa ◽  
Total Prostate Specific Antigen ◽  
Good Discriminator ◽  
Male Patients ◽  
Current Screening

Background: Prostate cancer is a leading cause of morbidity and mortality in our male population, thus screening initiatives will help to improve outcomes. The current screening marker, total prostate-specific antigen (PSA), is not prostate cancer specific. The development of percentage free PSA (%FPSA) has largely improved the detection of prostate cancer.Objectives: To assess the performance of %FPSA ratio at the 25% cut-off and its ability to distinguish between prostate cancer and benign prostatic lesions.Methods: This was a retrospective study conducted on male patients with total prostate-specific antigen values 10 ng/ml and with prostate histology results. Male patients with total prostate-specific antigen between 4 and 10 ng/ml had their free prostate-specific antigen determined together with the calculation of the free prostate-specific antigen ratio. The ratio was then correlated with prostate histology results to determine the presence of prostate cancer at the cut-off ratio of 25%.Results: Prostate cancer was detected in 28 (21.37%) patients out of the total population of 131. Ninety-two patients had a FPSA ratio of 25%, 22 (22.8%) of whom were found to have prostate cancer. Notably the sensitivity and specificity were found to be 86% and 27% respectively, with a positive predictive of value of 21% at this cut-off.Conclusions: The study demonstrates a %FPSA ratio of 25% not to be a good discriminator between prostatic cancerous and benign lesions. It is thus recommended that a prostate biopsy should be done based on clinical examination findings rather than the level of total prostate specific antigen from 0–10 ng/ml or %FPSA ratio.

scholarly journals Effects of Eight-Week Combined Resistance and Endurance Training on Serum Levels of Prostate Specific Antigen (PSA), Sex Hormone Binding Globulin (SHBG), and Phosphatase and Tensin Homolog (PTEN) in Men with Prostate Cancer

2022 ◽  
Vol 19 (4) ◽  
Author(s):  
Abbas Jafari ◽  
Hamid Arazi ◽  
Amirabbas Monazzami ◽  
Alireza Ghadian ◽  
Kambiz Hasrak
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Training Group ◽  
Serum Levels ◽  
Sex Hormone Binding Globulin ◽  
Aerobic Performance ◽  
Control Group ◽  
Strength Performance ◽  
Combined Training ◽  
Tensin Homolog

Background: Prostate cancer (PC) is the second most prevalent cancer and the sixth cancer leading to death in men worldwide. Objectives: The purpose of this study was to examine the effect of eight weeks of combined training on specific markers of prostate cancer in older adults. Methods: Twenty older adults (62 ± 7 years) with prostate cancer were divided randomly into the control (n = 10) and training (n = 10) groups. The training group performed exercise training in three sessions a week for eight weeks. Resistance training included two sets of 10 repetitions at 60 - 75% of one-repetition maximum, and endurance training contained treadmill running for 20 - 35 min at 60 - 75% of maximum heart rate. Bruce test, one-repetition maximum, and ELISA technique were used respectively to measure the aerobic performance, strength performance, and serum levels of prostate specific antigen (PSA), sex hormone binding globulin (SHBG), phosphatase and tensin homolog (PTEN), and testosterone (TS). A two-way analysis of variance with repeated measures was used to specify the differences. Results: Weight, fat percentage, Body Mass Index (BMI), waist-hip ratio (WHR), glucose, insulin, and PSA were significantly lower in the training group than the control group (P < 0.05). Furthermore, strength performance, aerobic performance, SHBG, TS, and PTEN were significantly higher in the training group than in the control group (P < 0.05). Conclusions: Combined training can have an influential role in physical condition improvement through decreasing the PSA serum level and increasing SHBG, TS, and PETEN serum levels, which helps patients with prostate cancer to be cured.

Primary Fibrinolysis as the Presenting Sign of Metastatic Prostate Cancer: One Case Report and Literature Review.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3966-3966
Author(s):  
Rongfu Zhou ◽  
Jian Ouyang ◽  
Bing Chen ◽  
Ming Zhou ◽  
Yong Xu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Blood Cell ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
Serum Levels ◽  
Fresh Frozen Plasma ◽  
Bone Lesions ◽  
Thrombin Time ◽  
Normal Range ◽  
Free Psa

Abstract Primary fibrinolysis revealing a prostatic adenocarcinoma is rare. Most of the case are limited to biological abnormalities. Here, we describe an unusual case of hematuria and primary fibriolysis as the presenting manifestation of metastatic prostate cancer in a 52-year-old man. The patient consulted for hematuria, ecchymosis and bleeding gums for a month. B-type ultrasound examination showed normal image of prostate. Peripheral blood test showed that the counts of white blood cell, red blood cell and platelet were all in normal range. APTT, prothrombin time and thrombin time were normal. But fibrinogen levels continued to lower than 1.1g/l despite infusions of cryoprecipitate and fresh frozen plasma. Further tests suggested that D-dimer was 9.58 mg/l (normal range: &lt;0.5mg/L), FDP 45 μg/ml, t-PA 90.30 ng/ml (1.00∼12.00 ng/ml), PAI-1 38.3 ng/ml (5.00∼45 ng/ml), α2-PI 118.00% (96.8∼118.8%), PLG 43.30% (57.8∼113.4%), prostate-specific antigen (PSA) 640.2 ng/ml (0∼4 ng/ml), Free PSA 64.2 ng/ml (0∼0.93 ng/ml). PET-CT revealed enhanced metabolizing rate of prostate with enlargement of lymph node in abdomen and multiple bone lesions including rib, vertebration and pelvis. Treatment with a luteinizing hormone-releasing hormone (LHRH) agonist (Diphereline) and a short course of an antiandrogen, led to normalization of all coagulation parameters within 2 weeks, and to clinical improvement and decline in the serum levels of PSA and fPSA. Three months later, the serum levels of PSA and fPSA were normal. We discuss the pathogenesis, differential diagnosis, and association of primary fibrinolysis with prostate cancer along with the management of this condition.

scholarly journals CAN PROSTATE-SPECIFIC ANTIGEN DENSITY AND FREE / TOTAL PROSTATE-SPECIFIC ANTIGEN RATIO PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER (GLEASON ≥ 7) IN PATİENTS DIAGNOSED PROSTATE CANCER ON BIOPSY WITH A PROSTATE-SPECIFIC ANTIGEN LEVEL OF 2.5 -10 NG/ML?

2021 ◽  
Author(s):  
Fatih Bicaklioglu ◽  
Hasan Aydin ◽  
Ahmet Özgür Güçtaş ◽  
Hamit Zafer Aksoy
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Sensitivity And Specificity ◽  
Prostate Biopsy ◽  
Specific Antigen ◽  
Free Psa ◽  
Total Prostate Specific Antigen ◽  
Prostate Specific Antigen Density ◽  
Clinically Significant ◽  
Total Psa

Introduction Many men with non-clinically significant PCa (N-CSPCa) will not progress to become symptomatic within their lifetime. If we can predict clinically significant PCa (CSPCa), we can prevent patients from unnecessary biopsies, overdiagnoses, and overtreatment. The purpose of this study was to determine whether PSAD and f/t PSA can predict CSPCa (Gleason ≥ 7) in patients diagnosed with prostate cancer on biopsy with a PSA level of 2.5-10 ng/ml or not. Materials and Methods 78 patients who underwent TRUSG-guided prostate biopsy with PSA 2.5-10.0 in our clinic between March 2017 - August 2020 and whose pathology result was reported as prostate adenocarcinoma, were retrospectively evaluated. In addition to the demographic content of the patients, PSA, free PSA, prostate size (with TRUSG), rectal examination findings and prostate biopsy pathology results were recorded. Clinically significant prostate cancer was defined as a Gleason score 7. Results The mean age of the patients was 66.9 ± 8.4, PSA value was 6.9 ± 1.8, free / total PSA ratio was 18 ± 8.1%, and PSA density was 0.150 ± 0.078. The P values of PSA, free PSA, PSAD, f/t PSA, and prostate volume between CSPCa and N- CSPCa groups were 0.010, 0.780, 0.001, 0.084, and 0.030, respectively. The area under the ROC curve (AUC) of the PSAD for predicting CSPCa was 0.719 with a 95% Cl (0.604–0.835), and the standard errors were 0.062 and 0.059, respectively. When PSAD cutoff was 0.130 for predicting CSPCa, sensitivity and specificity were 75% and 63%, respectively. Conclusion PSAD can be used for predicting CSPCa, but f/t PSA can not. PSAD is not a strong stand-alone tool with its sensitivity and specificity, but we suggest that PSAD can be a part of future nomograms for predicting CSPCa and future protocols for active surveillance. Key words:prostate-specific antigen; clinically significant prostate cancer

Sign in / Sign up

Export Citation Format

Share Document